Business
BATM expands COVID-19 diagnostic tests
BATM expands COVID-19 diagnostic tests.
About this update from Batm Advanced Communications Ltd.
[{"type":"text","content":"\n \n \n RNS Number : 0092T\n BATM Advanced Communications Ld\n 15 July 2020\n \n \n \n \n LEI: \n 213800FLQUB9J289RU66\n \n \n 15 July 2020\n \n \n \n \n \n BATM Advanced Communications Limited\n \n \n (\"BATM\" or \"the Group\")\n \n \n \n \n \n BATM expands COVID-19 diagnostic tests\n \n \n Launch of three new test kits to advance the diagnosis of COVID-19 and other respiratory illness \n \n \n \n \n \n BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces the launch of three new diagnostic kits to significantly advance the diagnosis of COVID-19 and other respiratory illnesses. \n \n \n \n \n \n Highlights\n \n \n · \n COVID-19 serologic test upgraded to measure the quantity of antibodies in the blood rather than just the presence or absence\n \n \n · \n COVID-19 antigen test upgraded to detect spike (S) gene to enable diagnosis of COVID-19 in people with low viral loads, increasing testing accuracy \n \n \n · \n New molecular diagnostics test developed to rapidly identify the specific respiratory virus or bacteria in someone presenting with symptoms of, or suspected to have pre-symptomatic respiratory illness \n \n \n \n \n \n The Group expects to commence sales and production of the kits at its Adaltis facility in Italy at the end of Q3/beginning of Q4 2020.\n \n \n \n \n \n COVID-19 serologic test\n \n \n \n \n \n The Group's serologic test for the detection of COVID-19 antibodies, as announced on 5 May 2020, has been advanced to be able to measure the quantity of antibodies in the blood rather than just identifying their presence or absence (qualitative test). The upgraded test measures both IgM antibodies, which are produced a few days after infection and remain in the blood for a short period, and IgG antibodies, which are longer-term (produced a few days after infection and remain in the blood for a few months) antibodies. It has the same levels of sensitivity and specificity as those of the market-leading brands, with sensitivity of 100.0% and specificity of 99.8%. \n \n \n \n \n \n This upgraded test was developed by the Group in response to the growing amount of medical research suggesting that the volume of antibodies in the blood of someone who has recovered from COVID-1...